Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lung cancer: targeted drug cocktails enter human testing

NCT ID NCT07286149

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 03, 2026 · Updated 7 times

Summary

This study tests a new targeted therapy called MK-1084, alone or combined with other drugs, in 190 people with advanced non-squamous non-small cell lung cancer that has a specific KRAS G12C mutation and has worsened after prior treatments. The main goals are to check safety and see if tumors shrink. It is an early-phase trial, so results are not yet known.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MK-1084 (targeted therapy) combined with patritumab deruxtecan, sacituzumab tirumotecan, or cetuximab
What this could lead to
If successful, this could lead to new combination treatment options for people with a specific type of advanced lung cancer that has stopped responding to prior therapies.
What could go wrong
This is an early-phase trial (Phase 1b/2) with a small number of participants, so the treatments may not prove effective or safe enough for wider use. Side effects from the drug combinations could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Apr 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) * Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene (KRAS) mutation of glycine to cysteine at codon 12 (G12C) mutations * Has documented disease progression after receiving 1-2 prior lines of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy and platinum-based chemotherapy * Has provided tumor tissue for biomarker analysis from an archival sample or a newly obtained core or excisional biopsy of a tumor lesion not previously irradiated * Participants with human immunodeficiency virus (HIV) infection must have well-controlled HIV on antiretroviral therapy (ART) per protocol Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements * Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease * Has evidence of any leptomeningeal disease * Has uncontrolled or significant cardiovascular disorder or cerebrovascular disease prior to allocation/randomization * Has one or more of the following ophthalmological conditions: a) Clinically significant corneal disease b) history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention * Has known additional malignancy that is progressing or has required active treatment within the past 3 years * Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use or current ILD, or suspected ILD * Has an active infection requiring systemic therapy * Has not adequately recovered from major surgery or has ongoing surgical complications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced or metastatic nonsquamous non-small cell lung cancer with KRAS G12C mutation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung adenocarcinoma lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung neoplasm malignant

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    28 sites in 11 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 0205)

    RECRUITING

    Athens, Attica, 115 28, Greece

  • Bradfordhill ( Site 0160)

    RECRUITING

    Santiago, Region M. de Santiago, 8420383, Chile

  • Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0162)

    RECRUITING

    Santiago, Region M. de Santiago, 7500653, Chile

  • Clermont Oncology Center ( Site 0041)

    RECRUITING

    Clermont, Florida, 34711, United States

  • FALP ( Site 0161)

    RECRUITING

    Santiago, Region M. de Santiago, 7500921, Chile

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0286)

    RECRUITING

    São José do Rio Preto, São Paulo, 15090-000, Brazil

  • Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0282)

    RECRUITING

    Barretos, São Paulo, 14784-400, Brazil

  • Guangdong Provincial People s Hospital ( Site 0300)

    RECRUITING

    Guangzhou, Guangdong, 510120, China

  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 0091)

    RECRUITING

    Pozuelo de Alarcón, Madrid, 28223, Spain

  • Hong Kong United Oncology Centre ( Site 0232)

    RECRUITING

    Jordan, 000000, Hong Kong

  • Hospital Clinic de Barcelona ( Site 0092)

    RECRUITING

    Barcelona, 08036, Spain

  • Hospital Paulistano ( Site 0280)

    RECRUITING

    São Paulo, São Paulo, 01321001, Brazil

  • Hospital São Lucas da PUCRS ( Site 0283)

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90610-000, Brazil

  • Hospital Universitario Virgen Macarena ( Site 0093)

    RECRUITING

    Seville, 41009, Spain

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 0176)

    RECRUITING

    Meldola, Forli-Cesena, 47014, Italy

  • Institut Català d'Oncologia - L'Hospitalet ( Site 0090)

    RECRUITING

    Hospitalet, Barcelona, 08908, Spain

  • Meir Medical Center ( Site 0181)

    RECRUITING

    Kfar Saba, 4428164, Israel

  • Papageorgiou General Hospital of Thessaloniki ( Site 0206)

    RECRUITING

    N.Efkarpia, Thessaloniki, 564 29, Greece

  • Prince of Wales Hospital ( Site 0231)

    RECRUITING

    Shatin, Hong Kong

  • Providence Oncology and Hematology Care Clinic - Westside ( Site 0059)

    RECRUITING

    Portland, Oregon, 97225, United States

  • Providence Portland Medical Center ( Site 0043)

    RECRUITING

    Portland, Oregon, 97213, United States

  • Queen Mary Hospital ( Site 0230)

    RECRUITING

    Hong Kong, 000000, Hong Kong

  • Severance Hospital, Yonsei University Health System ( Site 0080)

    RECRUITING

    Seoul, 03722, South Korea

  • Shaare Zedek Medical Center ( Site 0186)

    RECRUITING

    Jerusalem, 9103102, Israel

  • Sheba Medical Center ( Site 0180)

    RECRUITING

    Ramat Gan, 5265601, Israel

  • THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 0204)

    RECRUITING

    Athens, Attica, 115 27, Greece

  • UniversitaetsklInikum Tuebingen ( Site 0192)

    RECRUITING

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • University of Illinois Hospital & Health Sciences System ( Site 0044)

    RECRUITING

    Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.